Vaxart Balance Sheet Health
Financial Health criteria checks 5/6
Vaxart has a total shareholder equity of $80.0M and total debt of $4.3M, which brings its debt-to-equity ratio to 5.3%. Its total assets and total liabilities are $113.7M and $33.7M respectively.
Key information
5.3%
Debt to equity ratio
US$4.28m
Debt
| Interest coverage ratio | n/a |
| Cash | US$62.59m |
| Equity | US$80.01m |
| Total liabilities | US$33.74m |
| Total assets | US$113.75m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: NB11's short term assets ($71.5M) exceed its short term liabilities ($15.8M).
Long Term Liabilities: NB11's short term assets ($71.5M) exceed its long term liabilities ($18.0M).
Debt to Equity History and Analysis
Debt Level: NB11 has more cash than its total debt.
Reducing Debt: NB11's debt to equity ratio has reduced from 116.8% to 5.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NB11 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NB11 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 33.4% each year